연구성과로 돌아가기
2024 연구성과 (145 / 286)
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
| WoS | SCOPUS | Document Type | Document Title | Abstract | Authors | Affiliation | ResearcherID (WoS) | AuthorsID (SCOPUS) | Author Email(s) | Journal Name | JCR Abbreviation | ISSN | eISSN | Volume | Issue | WoS Edition | WoS Category | JCR Year | IF | JCR (%) | FWCI | FWCI Update Date | WoS Citation | SCOPUS Citation | Keywords (WoS) | KeywordsPlus (WoS) | Keywords (SCOPUS) | KeywordsPlus (SCOPUS) | Language | Publication Stage | Publication Year | Publication Date | DOI | JCR Link | DOI Link | WOS Link | SCOPUS Link |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ○ | ○ | Article | Study Design and Protocol for a Randomized Controlled Trial to Assess Long-Term Efficacy and Safety of a Triple Combination of Ezetimibe, Fenofibrate, and Moderate- Intensity Statin in Patients with Type 2 Diabetes and Modifiable Cardiovascular Risk Factors (ENSEMBLE) | Background: Atherogenic dyslipidemia, which is frequently associated with type 2 diabetes (T2D) and insulin resistance, contributes to the development of vascular complications. Statin therapy is the primary approach to dyslipidemia management in T2D, however, the role of non-statin therapy remains unclear. Ezetimibe reduces cholesterol burden by inhibiting intestinal cholesterol absorption. Fibrates lower triglyceride levels and increase high-density lipoprotein cholesterol (HDL-C) levels via peroxisome proliferator-activated receptor alpha agonism. Therefore, when combined, these drugs effectively lower non-HDL-C levels. Despite this, few clinical trials have specifically targeted non-HDL-C, and the efficacy of triple combination therapies, including statins, ezetimibe, and fibrates, has yet to be determined. Methods: This is a multicenter, prospective, randomized, open-label, active-comparator controlled trial involving 3,958 eligible participants with T2D, cardiovascular risk factors, and elevated non-HDL-C (>= 100 mg/dL). Participants, already on moderate-intensity statins, will be randomly assigned to either Ezefeno (ezetimibe/fenofibrate) addition or statin dose-escalation. The primary end point is the development of a composite of major adverse cardiovascular and diabetic microvascular events over 48 months. Conclusion: This trial aims to assess whether combining statins, ezetimibe, and fenofibrate is as effective as, or possibly superior to, statin monotherapy intensification in lowering cardiovascular and microvascular disease risk for patients with T2D. This could propose a novel therapeutic approach for managing dyslipidemia in T2D. | Kim, Nam Hoon; Lee, Juneyoung; Chon, Suk; Yu, Jae Myung; Jeong, In-Kyung; Lim, Soo; Kim, Won Jun; Song, Keeho; Cho, Ho Chan; Yu, Hea Min; Kim, Kyoung-Ah; Kim, Sang Soo; Lee, Soon Hee; Kim, Chong Hwa; Kwak, Soo Heon; Lee, Yong-ho; Chung, Choon Hee; Lee, Sihoon; Jin, Heung Yong; Lee, Jae Hyuk; Koh, Gwanpyo; Kim, Sang-Yong; Kim, Jaetaek; Lee, Ju Hee; Kim, Tae Nyun; Jeon, Hyun Jeong; Lee, Ji Hyun; Jeon, Jae-Han; Yoo, Hye Jin; Kim, Hee Kyung; Park, Hyeong-Kyu; Nam-Goong, Il Seong; Hong, Seongbin; Ahn, Chul Woo; Yu, Ji Hee; Park, Jong Heon; Park, Keun-Gyu; Park, Chan Ho; Joung, Kyong Hye; Ryu, Ohk-Hyun; Park, Keun Yong; Hong, Eun-Gyoung; Cha, Bong-Soo; Won, Kyu Chang; Chung, Yoon-Sok; Kim, Sin Gon | Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab,Anam Hosp, 73 Goryeodae Ro, Seoul 02841, South Korea; Korea Univ, Dept Biostat, Coll Med, Seoul, South Korea; Kyung Hee Univ, Kyung Hee Univ Hosp, Coll Med, Dept Endocrinol & Metab, Seoul, South Korea; Hallym Univ, Dept Internal Med, Kangnam Sacred Heart Hosp, Coll Med, Anyang, South Korea; Kyung Hee Univ, Coll Med, Kyung Hee Univ Hosp Gangdong, Div Rheumatol,Dept Internal Med, Seoul, South Korea; Seoul Natl Univ, Seoul Natl Univ Bundang Hosp, Dept Internal Med, Coll Med, Seongnam, South Korea; Univ Ulsan, Gangneung Asan Hosp, Dept Internal Med, Div Endocrinol & Metab,Coll Med, Kangnung, South Korea; Konkuk Univ, Sch Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea; Keimyung Univ, Sch Med, Dept Internal Med, Daegu 42601, South Korea; Eulji Univ, Daejeon Eulji Med Ctr, Dept Internal Med, Daejeon, South Korea; Dongguk Univ, Ilsan Hosp, Dept Internal Med, Div Endocrinol & Metab, Goyang, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Pusan, South Korea; Inje Univ, Busan Paik Hosp, Coll Med, Dept Internal Med, Pusan 614735, South Korea; Bucheon Sejong Hosp, Dept Internal Med, Bucheon, South Korea; Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea; Yonsei Univ, Wonju Coll Med, Dept Internal Med, Res Inst Metab & Inflammat, Wonju, South Korea; Gachon Univ, Dept Internal Med, Coll Med, Incheon 21565, South Korea; Jeonbuk Natl Univ, Jeonbuk Natl Univ Hosp, Div Endocrinol & Metab,Dept Internal Med, Res Inst Clin Med,Biomed Res Inst,Med Sch, Jeonju, South Korea; Hosp Myongji, Div Endocrinol, Dept Internal Med, Goyang, South Korea; Jeju Natl Univ, Coll Med, Jeju Natl Univ Hosp, Div Endocrinol & Metab,Dept Internal Med, Jeju, South Korea; Chosun Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Gwangju, South Korea; Chung Ang Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul, South Korea; Chungnam Natl Univ, Coll Med, Dept Internal Med, Daejeon, South Korea; Inje Univ, Coll Med, Dept Internal Med, Pusan, South Korea; Chungbuk Natl Univ, Chungbuk Natl Univ Hosp, Coll Med, Dept Orthoped, Cheongju 28644, South Korea; Daegu Catholic Univ, Sch Med, Dept Internal Med, Daegu, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Chilgok Hosp, Sch Med, Dept Internal Med, Daegu 41404, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Seoul 152050, South Korea; Chonnam Natl Univ, Med Sch, Dept Internal Med, Div Endocrinol & Metab, Gwangju 501757, South Korea; Soonchunhyang Univ Hosp, Univ Coll Med, Div Endocrinol & Metab, Dept Internal Med, Seoul 04401, South Korea; Univ Ulsan, Coll Med, Ulsan Univ Hosp, Dept Internal Med, Ulsan 44033, South Korea; Inha Univ, Coll Med, Dept Endocrinol & Metab, Incheon, South Korea; Yonsei Univ, Coll Med, Gangnam Severance Hosp, Dept Internal Med, Seoul, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, Ansan, South Korea; Natl Hlth Insurance Serv, Big Data Steering Dept, Goyang, South Korea; Kyungpook Natl Univ, Kyungpook Natl Univ Hosp, Sch Med, Dept Internal Med, Daegu, South Korea; Dong A Univ Coll Med, Dong A Univ Med Ctr, Div Endocrinol & Metab, Dept Internal Med, Pusan, South Korea; Chungnam Natl Univ Coll Med, Dept Internal Med, Div Endocrinol & Metab, Daejeon, South Korea; Hallym Univ, Div Endocrinol & Metab, Coll Med, Chuncheon Si, South Korea; Konyang Univ, Coll Med, Dept Diagnost Radiol, Konyang Univ Hosp, Taejon 302718, South Korea; Hallym Univ, Dongtan Sacred Heart Hosp, Dept Internal Med, Div Endocrinol & Metab, Hwaseong, South Korea; Yeungnam Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab, 170 Hyeonchung Ro, Daegu 42415, South Korea; Ajou Univ, Sch Med, Dept Endocrinol & Metab, 206 World Cup Ro, Suwon 16499, South Korea; Korea Univ, Coll Med, Dept Internal Med, Div Endocrinol & Metab,Anam Hosp, 73 Goryeodae Ro, Seoul 02841, South Korea | ; Choi, Kyung/C-4195-2018; Koh, Gwanpyo/AAV-2707-2020; Park, Kyoung Un/J-5473-2012; Kim, Sin Gon/KQU-7757-2024; Jeong, In-Kyung/AAI-6488-2020; Lee, Jae/AAF-5113-2021; Lim, Soo/AAU-8107-2020; Park, Chanho/AAT-3007-2020; Kim, Tae/AAV-5521-2020; Kwak, Soo Heon/H-1463-2011; KIM, SUNG MIN/U-5269-2017; Chon, Suk/AAV-3102-2020; Cho, Young/J-5669-2012; Woo, Jeong-Taek/AAF-7691-2021; Kim, Nam/U-1356-2019 | 57217397542; 57218683777; 8339069800; 55682098800; 7101712552; 26660890200; 55339618700; 7401740231; 20336747500; 55773268600; 57199440128; 56963431800; 57217663932; 24766040600; 25646358500; 56424219700; 57293078600; 7601394657; 22034630200; 55328571100; 8244935000; 57206876470; 57210199984; 57209683461; 36010711100; 7201833518; 58374693900; 36910340400; 57222279681; 57225209435; 55702042100; 57195363985; 7405766354; 35268155500; 14527795900; 55388512600; 57202558343; 59426578400; 37005715400; 8868796400; 59616589300; 8652654000; 57959977300; 57206373141; 16155874000; 7601582173 | kcwon@med.yu.ac.kr;yschung@ajou.ac.kr;k50367@korea.ac.kr; | ENDOCRINOLOGY AND METABOLISM | ENDOCRINOL METAB | 2093-596X | 2093-5978 | 39 | 5 | SCIE | ENDOCRINOLOGY & METABOLISM | 2024 | 4.2 | 27.0 | 0.53 | 2025-05-07 | 2 | 1 | Diabetes mellitus; type 2; Statin; Ezetimibe; Fibric acids; Dyslipidemias; Cardiovascular diseases | DENSITY-LIPOPROTEIN CHOLESTEROL; LIPID THERAPY; COMPLICATIONS; DYSLIPIDEMIA; NONADHERENCE; RETINOPATHY; REDUCTION; NEED | Cardiovascular diseases; Diabetes mellitus, type 2; Dyslipidemias; Ezetimibe; Fibric acids; Statin | ezefeno; ezetimibe; fenofibrate; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; adult; Article; cardiovascular risk factor; clinical trial protocol; combination drug therapy; controlled study; drug dose escalation; drug efficacy; drug megadose; drug safety; female; high density lipoprotein cholesterol level; human; major clinical study; male; middle aged; monotherapy; multicenter study; non insulin dependent diabetes mellitus; open study; pragmatic trial; prospective study; randomized controlled trial; study design | English | 2024 | 2024-10 | 10.3803/enm.2024.1995 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | Unveiling the chasm of economic burden from metastatic prostate cancer through a nationwide retrospective cohort study | ObjectiveTo analyze the clinical and economic consequences of the progression to castration-resistant status for patients with metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in South Korea.MethodsThis retrospective cohort study was conducted using National Health Insurance claims data from 2013 to 2021. Patients defined as newly diagnosed with mHSPC had an index date of first claim for metastatic PC between 2015 and 2016 and no exposure to CRPC medicines during the washout period. All-cause monthly medical and end-of-life costs were described for mHSPC and mCRPC. Descriptive statistics were used to analyze medical costs, and generalized estimating equations were used to evaluate the correlation between medical costs and significant variables, including disease progression, death, and clinical characteristics.ResultsOf the 3,739 patients with mHSPC included (mean 72.9 years), 779 progressed to mCRPC. The overall study population underwent a median 60.48-month follow-up period. The average monthly medical cost depending on CRPC progression was 1.5 times higher in the mCRPC than in the mHSPC group ($1,734.2 vs. $1,185.4). Monthly medical costs for those who progressed to mCRPC were 2.4 times higher one year after progression than one year before. In all groups, the average total medical costs gradually increased near mortality. Disease progression and death had a significant correlation with medical costs, by 1.7 times and 2.46 times, respectively.ConclusionThis study highlights the economic and health benefits of preventing progression to castration resistance in patients with mHSPC based on real-world data. | Kang, Hyunha; Kwak, Nayoung; Choo, Eunjung; Oh, Sung-Hee; Lee, Jiwon Sophie; Jeong, Chang Wook; Lee, Hankil | Ajou Univ, Coll Pharm, 206 Worldcup Ro, Suwon 16499, Gyeonggi Do, South Korea; Janssen Korea, Market Access, Seoul, South Korea; Ajou Univ, Res Inst Pharmaceut Sci & Technol RIPST, Suwon, South Korea; Kyungpook Natl Univ, Res Inst Pharmaceut Sci, Coll Pharm, BK21 FOUR Based Intelligent Novel Drug Discovery E, Daegu, South Korea; Seoul Natl Univ, Coll Med, Dept Urol, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Urol, Seoul, South Korea; Ajou Univ, Grad Sch, Dept Biohlth Regulatory Sci, Suwon, South Korea | ; Kim, Il Young/LLK-4732-2024 | 59416531500; 57579389800; 57218497400; 57188550994; 59417443000; 8879131000; 56802870700 | hankil@ajou.ac.kr; | CURRENT MEDICAL RESEARCH AND OPINION | CURR MED RES OPIN | 0300-7995 | 1473-4877 | 40 | 12 | SCIE | MEDICINE, GENERAL & INTERNAL;MEDICINE, RESEARCH & EXPERIMENTAL | 2024 | 2.2 | 27.0 | 0 | 2025-05-07 | 0 | 0 | Metastatic castration-resistant prostate cancer; metastatic hormone-sensitive prostate cancer; economic burden; medical costs; end-of-life costs; disease progression | POPULATION; COST | disease progression; economic burden; end-of-life costs; medical costs; Metastatic castration-resistant prostate cancer; metastatic hormone-sensitive prostate cancer | Aged; Aged, 80 and over; Cost of Illness; Disease Progression; Health Care Costs; Humans; Male; Middle Aged; Neoplasm Metastasis; Prostatic Neoplasms; Prostatic Neoplasms, Castration-Resistant; Republic of Korea; Retrospective Studies; abiraterone acetate; cabazitaxel; docetaxel; enzalutamide; estramustine; mitoxantrone; adult; aged; Article; cancer growth; cancer mortality; cancer patient; cancer prognosis; clinical feature; cohort analysis; comparative study; controlled study; economic aspect; follow up; health care cost; health care utilization; human; major clinical study; male; metastatic castration resistant prostate cancer; metastatic castration sensitive prostate cancer; population research; retrospective study; South Korea; terminal care; castration resistant prostate cancer; cost of illness; disease exacerbation; drug therapy; economics; epidemiology; metastasis; middle aged; mortality; pathology; prostate tumor; very elderly | English | 2024 | 2024-12-01 | 10.1080/03007995.2024.2425059 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |
| ○ | ○ | Article | A nationwide real-world study for evaluation of effectiveness and safety of T-DM1 in patients with HER2-positive metastatic breast cancer in Korea (KCSG BR19-15) | Purpose: This study aimed to investigate clinical practices and factors related to the outcomes of T-DM1 use in patients with HER2-positive metastatic breast cancer (mBC). Methods: We included patients with HER2-positive mBC who received T-DM1 as a palliative therapy between August 2017 and December 2018. The safety and outcomes of T-DM1, including overall response rate (ORR), progression-free survival (PFS), and overall survival (OS), were evaluated. A Cox proportional hazards model was used to estimate the hazard ratio and 95% confidence interval (CI) for mortality or progression to HER2-positive mBC. Results: In total, 824 patients were enrolled during the study period. The mean age of patients was 58 years, and 516 (62.6%) patients relapsed after curative treatment. Excluding a history of endocrine therapy, 341 (41.4%) patients previously received none or first-line chemotherapy, 179 (21.7%) received second-line therapy, and 303 (36.9%) received third-or later-line chemotherapy before T-DM1 therapy. During a median follow-up of 16.8 months, the ORR was 35%, the median PFS was 6.6 months, and the median OS was not reached. The clinical factors associated with the hazard of progression were age (2), advanced line of palliative chemotherapy (>2), prior pertuzumab use, and treatment duration of palliative trastuzumab (<10 months). Common grade 3-4 adverse events were thrombocytopenia (n = 107, 13.2%), neutropenia (n = 23, 2.8%), anemia (n = 21, 2.6%), and elevated liver enzyme (n = 20, 2.5%). Hypokalemia (<= 3.0 mmol/L) and any-grade bleeding events occurred in 25 (3.1%) and 94 (22.6%) patients, respectively. Conclusion: This is the first nationwide real-world study of T-DM1 use in patients with HER2-positive mBC in Korea. The effectiveness and toxicity profiles of T-DM1 in real-world practice were comparable to those in randomized trials. Moreover, patient factors and previous anti-HER2 therapy could predict the outcomes of T-DM1 therapy. | Baek, Sun Kyung; Jeong, Jae-ho; Jung, Kyunghae; Ahn, Hee Kyung; Kim, Min Hwan; Sohn, Joohyuk; Park, In Hae; Ahn, Jin Seok; Lee, Dae-Won; Im, Seock-Ah; Sim, Sung Hoon; Lee, Keun Seok; Hyun Kim, Jee; Shim, Hyun-Jeong; Chae, Yeesoo; Koh, Su-Jin; Lee, Hyorak; Lee, Jieun; Byun, Jae-Ho; Seol, Youngmi; Lee, Eun Mi; Jee, Hee-Jung; An, Hyonggin; Park, Eun Byeol; Suh, Young Ju; Lee, Kyoung Eun; Park, Yeon Hee | Kyung Hee Univ, Med Ctr, Dept Internal Med, Seoul, South Korea; Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea; Gachon Univ, Div Med Oncol, Dept Internal Med, Gil Med Ctr, Incheon, South Korea; Gachon Univ, Dept Internal Med, Gil Med Ctr, Incheon, South Korea; Yonsei Univ, Div Med Oncol, Coll Med, Seoul, South Korea; Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea; Korea Univ, Dept Internal Med, Div Oncol, Guro Hosp, Seoul, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, Seoul, South Korea; Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea; Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea; Seoul Natl Univ, Seoul Natl Univ Coll Med, Dept Internal Med, Bundang Hosp, Seongnam, South Korea; Chonnam Natl Univ, Dept Hematol Oncol, Med Sch, Gwangju, South Korea; Hwasun Hosp, Gwangju, South Korea; Kyungpook Natl Univ, Dept Internal Med, Chilgok Hosp, Daegu, South Korea; Ulsan Univ Hosp, Dept Hematol & Oncol, Ulsan, South Korea; Korea Canc Ctr Hosp, Div Hematol Oncol, Seoul, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Coll Med, Dept Internal Med,Div Med Oncol, Seoul, South Korea; Catholic Univ Korea, Incheon St Marys Hosp, Coll Med, Dept Internal Med, Incheon, South Korea; Pusan Natl Univ Hosp, Dept Internal Med, Div Hematol & Oncol, Coll Med, Busan, South Korea; Kosin Univ, Dept Internal Med, Gaspel Hosp, Busan, South Korea; Korea Univ, Coll Med, Dept Biostat, Seoul, South Korea; Inha Univ, Coll Med, Dept Biomed Sci, Incheon, South Korea; Ewha Womans Univ Hosp, Dept Hematol & Oncol, 1071 Anyangcheon Ro, Seoul 07985, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Dept Med, Div Hematol Oncol,Sch Med, 81 Irwon Ro, Seoul 06351, South Korea | ; Suh, Young/AAD-5737-2021; Im, Seock-Ah/J-5620-2012; Kim, Hyoungil/M-7288-2019; Lee, Dae-Won/JZT-4542-2024; Jee, Hee-Jung/AAY-9026-2020 | 36631425100; 57022763500; 57686095200; 50261094700; 56007980700; 57215667847; 25636160300; 56525813200; 57202974892; 34570185300; 25926764600; 17137276100; 56004266300; 35234958600; 57190793908; 55286016300; 38061483200; 58067353600; 57209110516; 14825635200; 57203206501; 57191924509; 7202277445; 58844410000; 35752438900; 7501517217; 35273175600 | oncolee@ewha.ac.kr;yhparkhmo@skku.edu; | THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | THER ADV MED ONCOL | 1758-8340 | 1758-8359 | 16 | SCIE | ONCOLOGY | 2024 | 4.2 | 27.1 | 0 | 2025-04-16 | 0 | 0 | HER2 positive; metastatic breast cancer; real-world data; T-DM1 | ANTIBODY-DRUG CONJUGATE; TRASTUZUMAB EMTANSINE; OPEN-LABEL; PHYSICIANS CHOICE; DERUXTECAN; PERTUZUMAB; LAPATINIB; DS-8201A; RECEPTOR; CAPECITABINE | HER2 positive; metastatic breast cancer; real-world data; T-DM1 | anthracycline; aspartate aminotransferase; epidermal growth factor receptor 2; lapatinib; liver enzyme; pertuzumab; trastuzumab; trastuzumab emtansine; adjuvant therapy; adult; aged; anemia; Article; bone metastasis; brain parenchymal metastasis; cancer growth; cancer hormone therapy; central nervous system metastasis; chemotherapy induced nausea and vomiting; clinical characteristics; clinical evaluation; clinical factor; clinical practice; controlled study; cox proportional hazard model; cumulative survival rate; demography; descriptive research; disease control rate; drug safety; drug withdrawal; ECOG Performance Status; epistaxis; febrile neutropenia; female; follow up; gingiva bleeding; hazard ratio; health insurance; heart ejection fraction; human; hypertransaminasemia; hypokalemia; immunohistochemistry; in situ hybridization; Kaplan Meier method; Korea; Korean Health Insurance Review and Assessment; liver metastasis; lung metastasis; lymph node metastasis; major clinical study; male; meningeal metastasis; menopause; metastatic breast cancer; middle aged; mortality; multiple cycle treatment; nationwide real world study; nausea and vomiting; neutropenia; noninterventional study; outcome assessment; overall response rate; overall survival; palliative therapy; partial response; pathological complete response; pleura effusion; premenopause; progression free survival; response evaluation criteria in solid tumors; retrospective study; skin metastasis; stereotactic radiosurgery; Strengthening the Reporting of Observational Studies in Epidemiology; thrombocytopenia; treatment duration; visceral metastasis; whole brain radiotherapy | English | 2024 | 2024 | 10.1177/17588359231225029 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Review | Systematic Assessment of Mechanisms, Developments, Innovative Solutions, and Future Perspectives of Microplastics and Ecotoxicity - A Review | As plastics become more ubiquitous, their impact on the environment and on human health cannot be overlooked. Once generated, micro- and nano-plastics end-up in the environment, causing widespread health and environmental risks. This is a significant environmental problem given the minuscule sizes of microplastics, and therefore warrants further investigation. This study presents a comprehensive review of the ecotoxicology of microplastics and methods for their degradation and decomposition besides discussing the fate and transport processes, recent progress, emerging strategies, challenges and potential future directions. The authors carefully evaluate the processes through which microplastics cause harm, from molecular interactions in species, to ecological impacts, and end with advances in microplastic biodegradation. Different kinds of microplastics found in the environment include polyethylene, polystyrene, polypropylene, polyvinyl chloride, polycarbonate, polyurethane, polypropylene, and polyethylene terephthalate. Analysis of microbial and enzymatic decomposition provides several swelling mitigation strategies designed to reduce environmental threats. In-depth investigations of microplastic ecotoxicity and biodegradation are being facilitated by interdisciplinary proposals in the areas of nanotechnology, new analytical methods, and synthetic biology. The extensive study helps understand microplastics comprehensively which in-turn ensures informed actions to mitigate the challenge of the environmental impact of microplastics for sustainable future. Microplastic ecotoxicity and biodegradation exhibit complex processes, changing shifts, innovative remedies, and future possibilities. Microplastic pollution's ecological effects are complicated and intertwined, necessitating comprehensive mitigation strategies. Novel insight into microbial degradation of microplastics, especially through the enzymatic action of PETase and MHETase are significant. Enzymatic degradation, microbial consortia, and nanomaterial-enhanced processes show how microplastic degradation techniques are advancing. image | Manikandan, S.; Preethi, B.; Deena, S. R.; Vijayan, D. S.; Subbaiya, R.; Vickram, Sundaram; Karmegam, N.; Kim, Woong; Govarthanan, M. | Saveetha Inst Med & Tech Sci SIMATS, Saveetha Sch Engn, Dept Biotechnol, Chennai 602105, Tamil Nadu, India; Copperbelt Univ, Sch Math & Nat Sci, Dept Biol Sci, Jambo Dr, Kitwe 21692, Zambia; Copperbelt Univ, Oliver R Tambo Afr Res Chair Initiat ORTARChI Envi, Kitwe 21692, Zambia; Vinayaka Missions Res Fdn VMRF DU, Aarupadai Veedu Inst Technol, Dept Civil Engn, Chennai 603104, Tamil Nadu, India; Govt Arts Coll Autonomous, PG & Res Dept Bot, Salem 636007, Tamil Nadu, India; Kyungpook Natl Univ, Dept Environm Engn, 80 Daehak Ro, Daegu 41566, South Korea | Govarthanan, Muthusamy/C-1491-2014; S, Manikandan/GZM-7135-2022; S, Vijayan/P-9514-2016; Muthusamy, Govarthanan/C-1491-2014; Subbaiya, R/AAR-2948-2021; D S, Vijayan/P-9514-2016; S, Vickram/ABG-9459-2020; Natchimuthu, Karmegam/J-4745-2019; Santhana Raj, Deena/HGV-5071-2022 | 55213168500; 57233833500; 57772435200; 59145295000; 55263515700; 55257689800; 6506043230; 55581636400; 54881927600 | kanishkarmegam@gmail.com;gova.muthu@gmail.com; | ADVANCED SUSTAINABLE SYSTEMS | ADV SUSTAIN SYST | 2366-7486 | 8 | 11 | SCIE | GREEN & SUSTAINABLE SCIENCE & TECHNOLOGY;MATERIALS SCIENCE, MULTIDISCIPLINARY | 2024 | 6.1 | 27.1 | 0.48 | 2025-05-07 | 5 | 7 | bioaccumulation; bioremediation; environmental contamination; enzymatic degradation; plastic pollution; toxicity | VETERINARY ANTIBIOTICS; MICROBIAL CONSORTIA; BIODEGRADATION; DEGRADATION; REMOVAL; WATER; EFFICIENCY; TOXICITY; INSIGHTS; ISOLATE | bioaccumulation; bioremediation; environmental contamination; enzymatic degradation; plastic pollution; toxicity | Biochemistry; Biodegradation; Chlorine compounds; Elastomers; Health risks; Microplastic; Plastic bottles; Polyethylenes; Polypropylenes; Polyvinyl chlorides; Ecotoxicity; Environmental contamination; Enzymatic Degradation; Future perspectives; Impact on the environment; Innovative solutions; Mechanism development; Microplastics; Plastic pollutions; Systematic assessment; Bioremediation | English | 2024 | 2024-11 | 10.1002/adsu.202400294 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Bioconverted extract of Sophorae fructus modulates the innate immune response in RAW264.7 macrophages and mouse splenocytes | Bioconversion process is the process of treating microorganisms or enzymes involved in fermentation, which aims to produce new functionality. We performed a bioconversion process in Sophorae fructus, which resulted in immune-stimulatory effects. The bioconverted S. fructus (BSFE) increased the expression of immune modulators, phagocytosis activity and the expression of CD80 and MHC class II in RAW264.7 cells. The TLR4-MAPK/NF-kappa B signaling pathway is involved in the activation of RAW264.7 cells by BSFE. In splenocytes, the BSFE increased the expression of pro-inflammatory cytokines and macrophage activation. After the bioconversion process, the genistin present in S. fructus before the bioconversion process decreased, and genistein was produced. The BSFE also alleviated the expression of immune modulators in lipopolysaccharide-induced activated RAW264.7 cells, which is considered an effect of the produced genistein by the bioconversion process. Taken together, this suggests that BSFE is considered to have immune-stimulatory and anti-inflammatory effects when excessive immune responses occur. | Park, Ju-Hwi; Lee, Eunbi; Nam, Ju-Ock | Kyungpook Natl Univ, Coll Agr & Life Sci, Sch Food Sci & Biotechnol, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Tailored Food Technol, Daegu 41566, South Korea | 59073815500; 57798039800; 7201496105 | namjo@knu.ac.kr; | JOURNAL OF FUNCTIONAL FOODS | J FUNCT FOODS | 1756-4646 | 2214-9414 | 116 | SCIE | FOOD SCIENCE & TECHNOLOGY;NUTRITION & DIETETICS | 2024 | 4 | 27.2 | 1.79 | 2025-05-07 | 6 | 6 | Bioconversion; Immune modulation; Macrophage; Sophorae fructus; Splenocyte | ACTIVATION; SYSTEM | Bioconversion; Immune modulation; Macrophage; Sophorae fructus; Splenocyte | English | 2024 | 2024-05 | 10.1016/j.jff.2024.106202 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Letter | Can striatal dopamine transporter uptake increase following CSF tap test in patients with idiopathic normal pressure hydrocephalus? | Kim, Minju; Park, Young Ho; Song, Yoo Sung; Kang, Kyunghun; Kim, SangYun | Seoul Natl Univ, Coll Med, Dept Neurol, Seongnam, South Korea; Seoul Natl Univ, Dept Neurol, Bundang Hosp, Seongnam, South Korea; Seoul Natl Univ, Coll Med, Coll Med, Seongnam, South Korea; Seoul Natl Univ, Bundang Hosp, Dept Nucl Med, Seongnam, South Korea; Kyungpook Natl Univ, Sch Med, Dept Neurol, Daegu, South Korea; Kyungpook Natl Univ, Chilgok Hosp, Dept Neurol, Daegu, South Korea | 58805577700; 55494470700; 23104155900; 55365592200; 7601593906 | kumimesy@snubh.org; | PARKINSONISM & RELATED DISORDERS | PARKINSONISM RELAT D | 1353-8020 | 1873-5126 | 121 | SCIE | CLINICAL NEUROLOGY | 2024 | 3.4 | 27.2 | 0 | 2025-05-07 | 0 | 0 | Idiopathic normal pressure hyderocephalus; Parkinson 's disease; Cerebrospinal fluid tap test; Dopamine transporter scan | SHUNT SURGERY | Cerebrospinal fluid tap test; Dopamine transporter scan; Idiopathic normal pressure hyderocephalus; Parkinson's disease | Corpus Striatum; Dopamine Plasma Membrane Transport Proteins; Humans; Hydrocephalus, Normal Pressure; Neostriatum; Spinal Puncture; carbidopa; dopamine transporter; levodopa; dopamine transporter; aged; bradykinesia; case report; cerebrospinal fluid tap test; clinical article; clinical feature; constipation; gait disorder; human; Letter; male; memory disorder; muscle rigidity; neurologic examination; normotensive hydrocephalus; nuclear magnetic resonance imaging; physical examination; synucleinopathy; tremor; urinary dysfunction; corpus striatum; diagnostic imaging; lumbar puncture; neostriatum; normotensive hydrocephalus | English | 2024 | 2024-04 | 10.1016/j.parkreldis.2024.106048 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Ribes fasciculatum var. Chinense leaf extract alleviates muscle atrophy caused by chronic inflammatory conditions through suppressing polarization into M1 macrophages | Scope: Ribes fasciculatum Siebold & Zucc. var. chinense Maxim. Leave extract (RFE) has been reported to be nontoxic and suitable for consumption as a food, with documented anti-allergic and anti-obesity effects. Skeletal muscle atrophy in various chronic inflammatory conditions has been a significant concern, yet the role of RFE in ameliorating muscle atrophy remains to be demonstrated. This study aims to investigate the regulation of muscle atrophy by RFE in chronic inflammatory conditions. Methods and results: C2C12 myoblasts were treated with conditioned medium from Raw264.7 macrophages induced with LPS to simulate an inflammatory condition, or with conditioned medium containing RFE. This study found that muscle atrophy is significantly exacerbated in the inflammatory conditions, while RFE markedly improves this condition. RFE was found to recover the diminished differentiation capacity of myoblasts that occurs in chronic inflammatory conditions. Importantly, RFE mediates inhibition of polarization into proinflammatory M1 macrophages in Raw264.7 cells. This indicates that afzelin, active compound of RFE, interferes with the binding of LPS to the TLR4/MD2 complex. Conclusion: These results suggest that RFE can improve muscle atrophy in chronic inflammatory states by disrupting the binding of LPS to the TLR4/MD2 complex and inhibiting the polarization of macrophages into M1 phenotype. | Seo, Yeonju; Lee, Eunbi; Nam, Ju-Ock | Kyungpook Natl Univ, Dept Food Sci & Engn, Daegu 41566, South Korea; Kyungpook Natl Univ, Res Inst Tailored Food Technol, Daegu 41566, South Korea | 58042612000; 57798039800; 7201496105 | namjo@knu.ac.kr; | JOURNAL OF FUNCTIONAL FOODS | J FUNCT FOODS | 1756-4646 | 2214-9414 | 119 | SCIE | FOOD SCIENCE & TECHNOLOGY;NUTRITION & DIETETICS | 2024 | 4 | 27.2 | 0 | 2025-05-07 | 0 | 0 | Muscle atrophy; Macrophage polarization; Chronic inflammation; M1 macrophage; Muscle differentiation | PGC-1-ALPHA; ACTIVATION | Chronic inflammation; M1 macrophage; Macrophage polarization; Muscle atrophy; Muscle differentiation | English | 2024 | 2024-08 | 10.1016/j.jff.2024.106332 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | ○ | Article | Silibinin alleviates small intestine damage induced by aerosol inhalation of ammonium sulfate and ammonium nitrate | Industrialization and urbanization produce hazardous particulate matter (PM), including ammonium compounds like (NH4)2SO4 4 ) 2 SO 4 and NH4NO3, 4 NO 3 , which comprise around 50 % of PM. Despite this, the influence of ammonium on intestinal inflammation remains unclear. We studied an ammonium mixture's effects on the intestine, finding elevated pro-inflammatory cytokines and oxidative stress in exposed mice, causing small intestine morphological changes. Investigating mitigation strategies, we assessed silibinin, an antioxidant from milk thistle seeds. Silibinin treatment in (NH4)2SO4- 4 ) 2 SO 4- and NH4NO3-exposed 4 NO 3-exposed mice significantly reduced inflammatory markers, alleviated oxidative stress, and preserved intestinal tissue integrity via the PI3K/AKT pathway. Our findings elucidate ammonium's potential impact on intestinal inflammation and highlight silibinin's therapeutic impact against PM-induced small intestine damage. | Park, Kanghyun; Kwon, Hong Ju; Kim, Hyeonjin; Kim, Eungyung; Kim, Chae Yeon; Huang, Ke; Liu, Zhibin; Yi, Jun Koo; Kim, Doyoon; Sung, Yonghun; Li, Shengqing; Wen, Weihong; Ryoo, Zae Young; Jang, Soyoung; Kim, Myoung Ok | Kyungpook Natl Univ, Res Inst Innovat Anim Sci, Dept Anim Sci & Biotechnol, Sangju Si 37224, Gyeongsangbug D, South Korea; Pohang Technopark Fdn, Adv Bio Convergence Ctr ABCC, Pohang 37668, Gyeongbuk, South Korea; Hankyong Natl Univ, Sch Anim Life Convergence Sci, Anseong 17579, South Korea; Livestock Res Inst, 186 Daeryongsan Ro, Yeongju 36052, Gyeongsangbuk D, South Korea; Daegu Gyeongbuk Med Innovat Fdn K MEDIhub, Preclin Res Ctr, 80 Cheombok Ro, Daegu 41061, South Korea; Fudan Univ, Huashan Hosp, Dept Pulm & Crit Care Med, Shanghai 200040, Peoples R China; Northwestern Polytech Univ, Inst Med Res, Xian 710072, Peoples R China; Kyungpook Natl Univ, Sch Life Sci, BK21 FOUR KNU Creat Biores Grp, Daegu 41566, South Korea | RYOO, ZAEYOUNG/AAQ-1573-2020; Liu, Zhibin/AAL-6838-2021 | 58530860300; 57217867533; 57343180400; 57217871658; 57966906800; 58639636600; 58640210100; 56182537200; 57223194600; 58903739800; 53981564000; 7102171031; 16937104900; 57139360300; 8934745900 | jangsy@knu.ac.kr;ok4325@knu.ac.kr; | JOURNAL OF FUNCTIONAL FOODS | J FUNCT FOODS | 1756-4646 | 2214-9414 | 120 | SCIE | FOOD SCIENCE & TECHNOLOGY;NUTRITION & DIETETICS | 2024 | 4 | 27.2 | 1.19 | 2025-05-07 | 2 | 2 | Air pollution; Ammonium; Colitis; Silibinin; Particulate matter | OXIDATIVE STRESS; EXPOSURE; HEALTH; PM2.5; PATHWAY | Air pollution; Ammonium; Colitis; Particulate matter; Silibinin | English | 2024 | 2024-09 | 10.1016/j.jff.2024.106362 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Silk sericin-based functional food for osteoporosis prevention and therapy | The development of new functional foods that can potentially reduce the risk of diseases, such as osteoporosis, has received increasing attention in recent years. Here we demonstrated that silk sericin-based functional food (SSBF) exerted preventive and therapeutic effects against bone loss. Sericin isolated at 70 degrees C for 60 min from the cocoon of Bombyx mori stimulated osteoblast differentiation by increasing osteoblastic gene expression while inhibiting receptor activator of nuclear factor-kappa B ligand (RANKL)-induced osteoclast differentiation in vitro. Micro-computed tomography analysis revealed that pre- and post-oral administration of SSBF increased bone mass in ovariectomized mouse model in vivo. Furthermore, dynamic bone histomorphometry analysis revealed that SSBF enhanced osteoblast activity and suppressed bone resorption by reducing the number of osteoclasts. These findings indicated the potential role of SSBF in preventing and being a therapeutic candidate for osteoporosis. | Jin, Xian; Che, Xiangguo; Lee, Dong-Kyo; Cui, Ying; Choi, Poo-Reum; Kim, Hyun-Ju; Lee, Ji Hae; Kweon, Haeyong; Kim, Seong-Gon; Choi, Je-Yong | Kyungpook Natl Univ, Dept Biochem & Cell Biol, Cell & Matrix Res Inst, Sch Med,Skeletal Dis Anal Ctr, Daegu 41944, South Korea; RDA, Natl Inst Agr Sci, Ind Insect & Sericulture Div, Wonju 55365, South Korea; Gangneung Wonju Natl Univ, Coll Dent, Dept Oral & Maxillofacial Surg, Kangnung 25457, South Korea | ; Kim, Seong-Gon/AAF-7553-2020; Choi, Je-Yong/AAR-7334-2021 | 57204810645; 54792660600; 57216603928; 58974396100; 58974835200; 57208650339; 56046902700; 7004390708; 27171913700; 7501391068 | kimhan911021@naver.com;xiangguo0622@naver.com;ehdehd7710@naver.com;yingcui126@gmail.com;cplcjm@naver.com;biohjk@knu.ac.kr;jihae@korea.kr;hykweon@korea.kr;kimsg@gwnu.ac.kr;jechoi@knu.ac.kr; | JOURNAL OF FUNCTIONAL FOODS | J FUNCT FOODS | 1756-4646 | 2214-9414 | 116 | SCIE | FOOD SCIENCE & TECHNOLOGY;NUTRITION & DIETETICS | 2024 | 4 | 27.2 | 1.79 | 2025-05-07 | 4 | 4 | Functional foods; Osteoporotic bone loss; Sericin-based functional food; preventing; osteoporosis | TOLL-LIKE RECEPTOR; BONE MASS; EXTRACTION; PROTEIN | Functional foods; Osteoporotic bone loss; Sericin-based functional food, preventing osteoporosis | English | 2024 | 2024-05 | 10.1016/j.jff.2024.106148 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | The effect of granulated collagen tripeptide on sarcopenia in aged mice compared with collagen tripeptide | This study investigates the efficacy of granulated collagen tripeptide (gCTP) in mitigating sarcopenia in aged mice compared to CTP. 58 weeks (male, n = 38) C57BL/6J mice were divided into 4 groups: an aging control, 0.03 % Gly-Pro-Hyp, 0.9 % CTP, and 0.9 % gCTP-supplemented group. gCTP administration significantly increased lean mass without altering body weight, indicating potential benefits in improving body composition in aged mice. Moreover, gCTP enhanced muscle synthesis pathways, including IGF1/PI3K/mTOR axis and myogenin expression, increasing muscle mass and strength. Additionally, gCTP reduced muscle and systemic inflammation, as evidenced by decreased levels of pro-inflammatory cytokines and myokines. Notably, gCTP enhanced intestinal absorption of peptides, potentially contributing to improved protein synthesis. gCTP demonstrated superior efficacy in alleviating sarcopenia and related symptoms in aged mice compared to CTP, attributed to differences in absorption. These findings provide insights into the potential of gCTP supplementation as a therapeutic strategy for sarcopenia. | Kim, Chae-Eun; Shin, Su-Kyung; Bae, Heekyong R.; Lee, Joong Su; Shin, Yong Chul; Kwon, Eun-Young | Kyungpook Natl Univ, Dept Food Sci & Nutr, 80 Daehak Ro,Buk Ku, Daegu 41566, South Korea; Kyungpook Natl Univ, Ctr Food & Nutr Genom Res, 80 Daehak Ro,Buk Ku, Daegu 41566, South Korea; Kyungpook Natl Univ, Ctr Beautiful Aging, 80 Daehak Ro,Buk Ku, Daegu 41566, South Korea; Amicogen Inc, Healthcare & Nutr Lab, Seongnam 52621, Gyeonggi, South Korea; Amicogen Inc, Jinju 52840, Gyeongsangnam, South Korea | 57200245142; 23988149900; 57191253762; 59182473800; 59183262900; 15765422500 | eykwon@knu.ac.kr; | JOURNAL OF FUNCTIONAL FOODS | J FUNCT FOODS | 1756-4646 | 2214-9414 | 119 | SCIE | FOOD SCIENCE & TECHNOLOGY;NUTRITION & DIETETICS | 2024 | 4 | 27.2 | 0 | 2025-05-07 | 0 | 0 | Granulation; Collagen tripeptide; Intestinal absorption; Sarcopenia; Aging | ADIPOSE-TISSUE; INFLAMMATION; HOMEOSTASIS; ABSORPTION; OBESITY | Aging; Collagen tripeptide; Granulation; Intestinal absorption; Sarcopenia | English | 2024 | 2024-08 | 10.1016/j.jff.2024.106318 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||||
| ○ | Meeting Abstract | THE EFFICACY OF SAFINAMIDE IN IMPROVING MOTOR SYMPTOMS AND THE QUALITY OF LIFE IN KOREAN PATIENTS WITH MOTOR FLUCTUATIONS | Kwon, D. -Y.; Baik, J.; Oh, E.; Cheon, S. -M.; Cho, J. W.; Sung, Y. H.; Kim, J-S.; Shin, H. -W.; Kim, J-M.; Park, M. Y.; Ma, H-I.; Park, J-H.; Koh, S. -B.; Choi, S. -M.; Park, J.; Lee, P. H.; Ahn, T. -B.; Kim, S. J.; Lyoo, C. H.; Lee, H. -W.; Kim, J. | Korea Univ, Ansan Hosp, Neurol, Coll Med, Ansan, South Korea; Inje Univ, Sanggye Paik Hosp, Seoul, South Korea; Chungnam Natl Univ, Coll Med & Hosp, Daejeon, South Korea; Dong A Univ, Sch Med, Busan, South Korea; Sungkyunkwan Univ, Samsung Med Ctr, Sch Med, Seoul, South Korea; Gachon Univ, Gil Med Ctr, Coll Med, Incheon, South Korea; Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea; Chung Ang Univ Hosp, Seoul, South Korea; Seoul Natl Univ, Bundang Hosp, Coll Med, Bundang Hosp, Seoul, South Korea; Yeungnam Univ, Coll Med, Daegu, South Korea; Hallym Univ, Hallym Univ Sacred Heart Hosp, Coll Med, Anyang, South Korea; Soonchunhyang Univ, Bucheon Hosp, Bucheon, South Korea; Korea Univ, Coll Med, Guro Hosp, Seoul, South Korea; Chonnam Natl Univ, Chonnam Natl Univ Hosp, Med Sch, Gwangju, South Korea; Inje Univ, Haeundae Paik Hosp, Busan, South Korea; Yonsei Univ, Coll Med, Seoul, South Korea; Kyung Hee Univ Hosp, Seoul, South Korea; Inje Univ, Busan Paik Hosp, Coll Med, Busan, South Korea; Yonsei Univ, Gangnam Severance Hosp, Coll Med, Seoul, South Korea; Kyungpook Natl Univ, Daegu, South Korea; Eisai Korea Inc, Dept Med, Seoul, South Korea | Lee, Jun-Hyuk/KOC-2534-2024; Oh, Eungseok/AAL-8935-2020; Ahn, Tae-Beom/AAG-1309-2021 | PARKINSONISM & RELATED DISORDERS | PARKINSONISM RELAT D | 1353-8020 | 1873-5126 | 122 | SCIE | CLINICAL NEUROLOGY | 2024 | 3.4 | 27.2 | 0 | English | 2024 | 2024-05 | 바로가기 | 바로가기 | ||||||||||||||||
| ○ | Article | Crystal growth, luminescence, and scintillation properties of Zn2Te3O8 crystal for 0νββ decay search | A single crystal of Zn2Te3O8 (ZTO) was grown using the conventional Czochralski technique. TGA analysis showed that the melting point of ZTO is 681 degrees C, while it exhibits a structural phase transition at 621 degrees C. The powder X-ray diffraction analysis of ZTO confirmed that it possesses a single crystalline monoclinic structure with the C2/c space group. An indirect band gap of 3.75 eV was estimated for the ZTO crystal based on its absorption spectrum. The X-ray-induced luminescence of the grown crystal comprised a broad band peaking at 565 nm, which can be tentatively assigned to the self-trapped exciton emission from the (Te3O8)(4-) molecular complexes. The photoluminescence measured under 280 nm excitation showed a broad band luminescence peaking at about 600 nm, and its intensity was significantly enhanced upon cooling the crystal from 300 K to 10 K. The photoluminescence decay time under 280 nm excitation was shown to have two exponential components in the range from 10 K to 175 K, which became a single exponential upon further heating the crystal. Low scintillation light was observed at room temperature both under alpha- and beta-particle excitations from Am-241 and Sr-90 sources, respectively. The scintillation light yield measured under beta-particle excitation from the Sr-90 source was enhanced by about five orders of magnitude at 10 K in comparison to that at 300 K. The scintillation light yield measured at 10 K under the same experimental conditions for ZTO in comparison with the well-known cryogenic scintillator Li2MoO4 (LMO) was shown to have four times higher scintillation light. A single-crystal ingot of ZTO was obtained for the first time; however, it had several cracks due to its phase transition. Notably, scintillation at low temperatures for a Te-based crystal was observed for the first time. These preliminary findings are very promising and show that ZTO will be a good candidate for cryogenic phonon scintillation detectors for the 0 nu beta beta decay search of Te-130. | Khan, Arshad; Kim, H. J.; Kim, Yeongduk; Lee, Moo Hyun; Abdalla, Ayman M.; Algethami, Jari S. | Najran Univ, Fac Arts & Sci, Dept Phys, Najran, Saudi Arabia; Najran Univ, Promising Ctr Sensors & Elect Devices PCSED, POB 1988, Najran 11001, Saudi Arabia; Kyungpook Natl Univ, Dept Phys, Daegu 41566, South Korea; Inst Basic Sci IBS, Ctr Underground Phys, Daejeon 34126, South Korea; Univ Sci & Technol UST, IBS Sch, Daejeon 34113, South Korea; Najran Univ, Coll Sci & Arts, Dept Chem, Najran 11001, Saudi Arabia | Algethami, Jari/GYE-0257-2022; Khan, Arshad/ABB-1566-2021; Abdalla, A./Q-9467-2019; Kim, Hong Joo/AAE-1178-2022 | hongjoo@knu.ac.kr; | CRYSTENGCOMM | CRYSTENGCOMM | 1466-8033 | 26 | 2 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;CRYSTALLOGRAPHY | 2024 | 2.6 | 27.4 | 0 | ZNMOO4 SINGLE-CRYSTALS; REFINEMENT; MORPHOLOGY; PBMOO4 | English | 2024 | 2024-01-02 | 10.1039/d3ce01032e | 바로가기 | 바로가기 | 바로가기 | |||||||||||
| ○ | ○ | Article | Synthesis of Superhydrophobic Fluorescent Dyes Based on Coumarin-benzoxazole Derivatives and Their Dyeability Toward Unmodified Polypropylene Fibers | Three novel kinds of coumarin-benzoxazole-based superhydrophobic fluorescent dyes were synthesized. To induce the affinity to polypropylene, an extremely hydrophobic material, a dibutyl group was introduced into the coumarin moiety and one methyl, two methyl, and tertiary butyl groups were introduced into the benzoxazole moiety to obtain the three dyes, respectively. The optical properties of all three dyes were very similar because they were obtained via the introduction of different alkyl groups into the same fluorophore. Different alkyl substituents introduced into benzoxazole significantly affected its fluorescence properties, polypropylene affinity, and washability. In addition, the effects of dye concentration and dyeing temperature on the color strength and fluorescence emission intensity were investigated. Overall, the three developed fluorescent dyes applied well to the polypropylene fabric using the general dyeing method and showed excellent washability. | Lee, Junheon; Jeon, Kanghoon; Kim, Taekyeong | Kyungpook Natl Univ, Coll Engn, Dept Text Syst Engn, Daegu, South Korea | 57195904688; 58964396600; 24587275700 | taekyeong@knu.ac.kr; | FIBERS AND POLYMERS | FIBER POLYM | 1229-9197 | 1875-0052 | 25 | 12 | SCIE | MATERIALS SCIENCE, TEXTILES;POLYMER SCIENCE | 2024 | 2.3 | 27.4 | 0.32 | 2025-05-07 | 1 | 1 | Fluorescence; Coumarin; Polypropylene; Dyeing; Hydrophobicity | DIFFERENCE; TEXTILE; COLOR | Coumarin; Dyeing; Fluorescence; Hydrophobicity; Polypropylene | Alkyl Groups; Fluorescence; Fluorescent Dyes; Polypropylene; Vat Dyes; Superhydrophobicity; Benzoxazole; Benzoxazole derivatives; Coumarin; Dye-ability; Fluorescent dyes; Hydrophobic Material; Superhydrophobic; Synthesised; Tertiary butyl groups; Washability; Vat dyes | English | 2024 | 2024-12 | 10.1007/s12221-024-00775-2 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | ||
| ○ | ○ | Article | Determination of the Hydroxyl Radical Reaction Rate Constant of Amines in the Aqueous Phase | Amines are volatile, alkaline, water-soluble organic compounds that have been studied because of their significant contribution to atmospheric pollution in terms of new particle formation, ultrafine particle growth, and the neutralization of aerosol acidity. Although numerous studies have investigated the gas-phase kinetics of amine oxidation by the hydroxyl (OH) radicals, aqueous-phase reactions have not been extensively explored. Herein, we investigated the bulk aqueous-phase kinetics of the oxidation of alkylamines and alkanol amines by OH radicals using relative rate kinetics. The experimentally calculated rate constants at pH 5 for monoethanolamine (MEA), diethanolamine, triethanolamine, and diethylamine were 4.6 +/- 0.27 x 10(8), 9.3 x 10(8), 4.9 x 10(8), and 3.7 x 10(8) M-1 s(-1), respectively. The oxidation rate of MEA gradually increased by 10-20% across a pH range of 2.0-6.0. Amine oxidation kinetics was also assessed in relation to the structural positioning of the hydroxyl and alkyl groups, which induce steric hindrance. In addition, under rural, urban, and marine scenarios, the photo-Fenton reaction resulted in 100, 60, and 40% degradation of MEA, whereas the Fenton reaction led to only 40, 15, and 8% degradation, respectively, after 20 min, illustrating the importance of the catalytic effect of iron in amine photodegradation and its kinetics. The atmospheric lifetimes of amines were calculated from the observed rate constants to predict the fate of amines in the atmosphere. Product analysis and model fitting of experimental data were used to confirm that hydrogen abstraction at alpha-carbon or beta-carbon rather than the terminal methyl group is the dominant pathway under relevant atmospheric conditions. The obtained results strengthen the understanding of the photochemical oxidation kinetics of amines and can help predict the lifetime of amines in the aqueous phase and, hence, their partitioning into the gas and particle phases. | Ullah, Atta; Afzal, Aqeel; Lim, Ho-Jin | Kyungpook Natl Univ, Sch Architecture Civil Environm & Energy Engn, Daegu 41566, South Korea; Univ Punjab, Inst Energy & Environm Engn, Lahore 54590, Pakistan | Afzal, Aqeel/JKL-1217-2023 | 59179204600; 57190047665; 56883100200 | hjlim@knu.ac.kr; | ACS EARTH AND SPACE CHEMISTRY | ACS EARTH SPACE CHEM | 2472-3452 | 8 | 7 | SCIE | CHEMISTRY, MULTIDISCIPLINARY;GEOCHEMISTRY & GEOPHYSICS | 2024 | 2.9 | 27.5 | 0 | 2025-04-16 | 0 | 0 | amine; aqueous phase; OH oxidation; rate constant; degradation | SECONDARY ORGANIC AEROSOL; OXIDATIVE-DEGRADATION; PULSE-RADIOLYSIS; CARBOXYLIC-ACIDS; SULFURIC-ACID; KINETICS; PARTICLE; FENTON; IRRADIATION; CHEMISTRY | amine; aqueous phase; degradation; OH oxidation; rate constant | English | 2024 | 2024-06-14 | 10.1021/acsearthspacechem.4c00047 | 바로가기 | 바로가기 | 바로가기 | 바로가기 | |||
| ○ | ○ | Article | Semantic Networks of Election Fraud: Comparing the Twitter Discourses of the US and Korean Presidential Elections | Traditional news outlets, such as newspapers and television, are no longer major sources of news. These media channels have been replaced by social platforms, which have increased in value as information distributors. This change in communication is an underlying reason for the election fraud controversies that occurred in the United States and South Korea, which hold high standards of democracy, during similar periods. This study investigates a model for sharing political disputes over social networks, especially Twitter, and illustrates the influence of political polarization. This study examines Twitter content around the presidential elections in the United States and South Korea in 2020 and 2022, respectively. It applies semantic network analysis and structural topic modeling to describe and compare the dynamics of online discourse on the issue of election fraud. The results show that online spaces such as Twitter serve as public spheres for discussion among active political participants. Social networks are key settings for forming and spreading election fraud controversies in the United States and South Korea, with differences in content. In addition, the study applies large-volume text data and new analytical methods such as the structural topic model to examine the in-depth relationships among political issues in cyberspace. | Lee, Jongmyung; Chung, Chung Joo; Kim, Daesik | Kangwon Natl Univ, Dept Media & Commun, Chunchon 24341, South Korea; Kyungpook Natl Univ, Dept Media & Commun, Daegu 41566, South Korea; Kyungpook Natl Univ, Dept Polit Sci & Diplomacy, Daegu 41566, South Korea | 58929746800; 55463815000; 57571326900 | journaleest@kangwon.ac.kr;cjchung@knu.ac.kr;daesik.kim@knu.ac.kr; | SOCIAL SCIENCES-BASEL | SOC SCI-BASEL | 2076-0760 | 13 | 2 | ESCI | SOCIAL SCIENCES, INTERDISCIPLINARY | 2024 | 1.7 | 27.5 | 0 | 2025-05-07 | 0 | 0 | election fraud; political communication; presidential elections; comparative analysis; Twitter | SOCIAL MEDIA; CENTRALITY; AUDIENCES | comparative analysis; election fraud; political communication; presidential elections; Twitter | English | 2024 | 2024-02 | 10.3390/socsci13020094 | 바로가기 | 바로가기 | 바로가기 | 바로가기 |
페이지 이동: